Cerdulatinib 13C4

[13C4]-Cerdulatinib is a stable isotope labeled version of the small molecule drug Cerdulatinib. Cerdulatinib is a dual inhibitor of Janus kinase (JAK) and spleen tyrosine kinase (SYK), which are both important signaling pathways in immune cells. This drug has shown promising results in preclinical studies for the treatment of several autoimmune diseases, including rheumatoid arthritis and lupus. [13C4]-Cerdulatinib is used in pharmacokinetic studies to track the metabolism and distribution of the drug in the body. By labeling four carbon atoms with the stable isotope carbon-13, researchers can easily differentiate the labeled drug from the unlabeled drug using mass spectrometry. This allows for precise measurements of drug levels in plasma, tissues, and urine, as well as information on drug clearance and half-life. In terms of chemical information, [13C4]-Cerdulatinib has a molecular formula of C21H16D4N6O3S and a molecular weight of 468.5 g/mol. It is a yellow powder that is soluble in DMSO and has a purity of at least 98%. The labeled drug is manufactured using synthetic chemistry techniques and undergoes rigorous quality control to ensure its stability and accuracy in pharmacokinetic studies. Overall, [13C4]-Cerdulatinib is a valuable tool for understanding the pharmacokinetics of the drug Cerdulatinib and may contribute to the development of effective treatments for autoimmune diseases.